Aptinyx (APTX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 24, 2021 4:05 PM EDTPhase 2 studies in fibromyalgia and painful DPN enrolling as planned data readouts expected in 1H 2022
Phase 2 study in cognitive impairment expected to recommence imminently data readout expected in 2H 2022
Reported data from Phase 2 exploratory study of NYX-783 in PTSD, supporting further clinical development meeting with FDA to discuss future development path April 29, 2021
Strong cash position expected to support operations through multiple clinical data readouts and into 2023
Conference call today at 5:00 p.m. EST
EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq:... More
